Foralumab reduced microglial activity in people with nonactive SPMS, and this was linked to reductions in proinflammatory ...

Neffy nasal spray shows comparable efficacy to IM epinephrine for type I allergic reactions, with 92.3% symptom resolution after 1 dose.

Stanford's potential universal vaccine promises to shield against COVID, flu, and more. Could one spray change how we fight ...

Acute Respiratory Distress Syndrome (ARDS) remains a major cause of morbidity and mortality in critically ill patients worldwide, despite advances in ...

Researchers in Maryland are testing an experimental treatment designed to block common respiratory viruses – from colds, the ...

If proven effective in humans, this vaccine could potentially eliminate the need for separate annual jabs for illnesses like ...